Scpharmaceuticals INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
MannKind Corporation has completed its acquisition of scPharmaceuticals Inc. for $5.35 per share in cash plus a contingent value right, making scPharmaceuticals a wholly-owned subsidiary.
scPharmaceuticals Inc. obtained a $10.0 million unsecured promissory note from MannKind Corporation to support operations during their pending merger.
MannKind Corporation announced a definitive merger agreement to acquire scPharmaceuticals Inc. for an upfront cash payment of $5.35 per share plus contingent value rights up to $1.00 per share, expanding its presence in cardiometabolic medicine.
scPharmaceuticals Inc. secures an extension for its critical SmartDose drug delivery system supply agreement with West Pharmaceutical Services until December 31, 2027.
scPharmaceuticals Inc. announced strong second quarter 2025 financial results, driven by a 99% increase in FUROSCIX net revenue and significant growth in doses shipped.
scPharmaceuticals Inc. announced the successful election of three Class II Directors and the approval of its independent auditor and executive compensation at its Annual Meeting of Stockholders held on June 3, 2025.
scPharmaceuticals announced a 93% increase in FUROSCIX revenue for Q1 2025, driven by expanded indications and increased prescription fills.
scPharmaceuticals announces positive financial results for Q4 and full year 2024, driven by significant revenue growth of FUROSCIX and FDA approval for chronic kidney disease indication.
scPharmaceuticals reports significant revenue growth for Q4 and full year 2024, driven by increased FUROSCIX sales and strategic expansion efforts.
8-K: scPharmaceuticals Inc. Announces Potential Delay in sNDA Submission for SCP-111 Combination Product
scPharmaceuticals Inc. has reported variability in shelf-life testing of its SCP-111 Combination Product, potentially delaying its sNDA submission beyond the targeted January 2025 timeframe.
scPharmaceuticals announced a 164% year-over-year increase in FUROSCIX revenue for Q3 2024, alongside a $125 million financing to support operations through expected profitability.
scPharmaceuticals announced a 33% sequential increase in net FUROSCIX revenue for Q2 2024, alongside securing a significant financing package to extend its cash runway through expected profitability.
scPharmaceuticals has issued warrants to purchase common stock and announced a $53.5 million underwritten offering of shares and pre-funded warrants.
scPharmaceuticals Inc. has entered into a $75 million term loan facility, sold revenue participation rights for $50 million, and received FDA approval to expand the FUROSCIX indication to include NYHA Class IV heart failure patients.
scPharmaceuticals Inc. held its annual meeting on June 11, 2024, electing three Class I directors and approving several proposals including the ratification of the company's accounting firm.
scPharmaceuticals Inc. announced that approximately 47,000 FUROSCIX doses have been prescribed since launch, with 24,000 doses filled through March 31, 2024.
scPharmaceuticals announced its first quarter 2024 financial results, highlighting a significant increase in FUROSCIX revenue despite a cyberattack impacting doses filled.
scPharmaceuticals announced its fourth quarter and full-year 2023 financial results, highlighting significant revenue growth for FUROSCIX and progress in its clinical development programs.